Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial - Gilead Sciences

9/12/2024

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial  Gilead SciencesGilead's twice-yearly shot cut HIV infections by 96% in trial  CNBCAn injectable HIV-prevention drug is highly effective — but wildly expensive  NBC NewsTwice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill  CNNGilead’s (GILD) Twice-Yearly Shot Prevents 96% of HIV Cases in Study  Bloomberg...

Original

Tags: cases | company | cut | daily | drug | risk | shot | trial

---